Recent News

• 12.12.2025 - ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe
• 12.02.2025 - Piper Sandler 37th Annual Healthcare Conference
• 12.02.2025 - December 2, 2025 - December 4, 2025 : Piper Sandler 37th Annual Healthcare Conference
• 12.02.2025 - December 2, 2025 - December 4, 2025 : Piper Sandler 37th Annual Healthcare Conference
• 11.17.2025 - Jefferies Global Healthcare Conference in London
• 11.13.2025 - New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
• 11.06.2025 - November 6, 2025 - November 8, 2025 : LUGPA 2025 Annual Meeting
• 11.06.2025 - November 6, 2025 - November 8, 2025 : LUGPA 2025 Annual Meeting
• 11.05.2025 - Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
• 11.03.2025 - November 3, 2025 - November 5, 2025 : BIO-Europe

Recent Filings

• 12.12.2025 - EX-99.1 EX-99.1
• 12.12.2025 - 8-K Current report
• 11.10.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 11.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.05.2025 - EX-99.1 EX-99.1
• 11.05.2025 - 8-K Current report
• 10.20.2025 - DEF 14C Other definitive information statements
• 10.08.2025 - PRE 14C Other preliminary information statements